echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Distal ischemia preconditioning intervention after moderate ischaemic stroke

    Distal ischemia preconditioning intervention after moderate ischaemic stroke

    • Last Update: 2023-01-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    This article is from NEJM Journal Watch


    Remote Ischemic Conditioning Intervention After Moderate Ischemic Stroke

    Distal ischemia preconditioning intervention after moderate ischaemic stroke


    Reviewed by Anthony S.
    Kim, MD


    A proof-of-principle study suggests benefits, but there are some methodological problems
    with the study.


    Distal ischaemic preconditioning refers to a protective strategy circulating between ischaemia and reperfusion within a vascular region (e.
    g.
    , arm) with the goal of inducing ischaemic tolerance in distal target tissues (e.
    g.
    , brain) to improve outcomes
    .
    Small clinical trials were inconclusive
    .
    In the largest randomized controlled trial to date, the investigators recruited 1,893 patients with acute moderate ischemic stroke (National Institutes of Health Stroke Scale score, 6~16 points) in 55 medical centers in China in 55 medical centers in China, and randomized them into two groups, both receiving usual care according to guidelines, in addition to receiving or not receiving distal ischemia pretreatment
    , respectively.
    Patients receiving intravenous thrombolysis or embolectomy were excluded
    .
    Open-label interventions included the application of auto-pneumatic pressurized pneumatics twice daily, 5 cycles of cuff inflation and deflation of bilateral upper extremities, each cycle inflated for 5 minutes (up to 200 mmHg), followed by 5 minutes of deflation for 10~14 days
    .

    One hundred and one hundred and seventeen patients were excluded
    after randomization.
    Subsequently, 582 (67.
    4%) of the 863 patients in the intervention group achieved excellent functional outcomes (modified Rankin scale score, 0 [asymptomatic] or 1 [mild symptoms without disability]) compared with 566 of 913 patients (62.
    0%) in the control group, a significant difference of 5.
    4% between the two groups (P = 0.
    02).

    Adverse events were numerically more numerous in the intervention group (59/863 vs.
    51/913), but six adverse events judged to be relevant to the intervention were redness (3), petechiae (2) and dizziness (1).

    comments

    Given that 6% of patients were rapidly excluded after randomization, that results had not been reported by the primary intention-to-treat analysis pre-specified in the statistical analysis plan, and that the trial was open-label rather than sham designed, this is particularly concerning because of the importance of proof-of-principle trials evaluating novel therapies for stroke
    .
    However, if these results are validated and reproduced, this could become the basis for
    a broadly applicable and significant neuroprotective approach.


    Articles that were commented on

    Chen H-S et al.
    Effect of remote ischemic conditioning vs usual care on neurologic function in patients with acute moderate ischemic stroke: The RICAMIS randomized clinical trial.
    JAMA 2022 Aug 16; 328:627.
    (https://doi.
    org/10.
    1001/jama.
    2022.
    13123)


    A collection of NEJM journals

    NEJM Journal Watch is published by NEJM Group, inviting internationally renowned doctors to review important papers in the field of medicine and help doctors understand and apply the latest progress
    .
    "NEJM Medical Frontiers" is translated several times a week, published on the app and official website, and 2-3 selected articles are published
    on WeChat.


    Copyright InformationThis article was translated, written or commissioned by Jiahui Medical Research and Education Group (J-Med) in collaboration with the New England Journal of Medicine (NEJM) for NEJM Medical Frontiers
    .
    The full text of the Chinese translation and the figures contained therein are exclusively licensed
    by NEJM Group.
    If you want to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
    cn
    .
    Unauthorized translation is an infringement and the copyright owner reserves the right to
    pursue legal liability.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.